东莞招聘

工作职责:

ROLE SUMMARY

Pfizer CentreOne (PC1) is a global contract development and manufacturing organization (CDMO) embedded within Pfizer generating $800M+ in revenue. We leverage strategic Pfizer manufacturing plants as well as science and technology resources to manufacture medicine for biopharmaceutical companies. We focus on custom API synthesis, sterile injectable fill-finish and highly potent oral solid dose; and are a leading supplier of steroid and hormone APIs and intermediates. For almost 50 years, we’ve manufactured complex compounds for our biopharmaceutical partners. Our dedicated team of contract manufacturing experts guide our partners’ drugs safely from development (phase 2 or later) through commercialization. Pfizer CentreOne also has a Corporate Sponsored Agreements team that manages trailing manufacturing supply agreements related to Pfizer M&A, licensing, divestitures; M&A activity could include animal health, infusion therapy, generic pharmaceuticals. Pfizer CentreOne reports into the Hospital Business within Pfizer Innovative Medicines.

Reporting to the Custom Business China Lead, the China BD (Senior) Manager will initially be responsible for developing the Hangzhou business pipeline through new opportunity identification, deal due diligence, proposal development, contract negotiation, internal consultation with manufacturing, R&D, regulatory, supply chain, contract execution and project management.  This role will contribute to define and drive the next phase of growth and optimize short, medium and long-term PC1 strategies in China for the existing Hangzhou Site .

This role will work closely with other PC1 business areas, Pfizer China and various PGS sites in China.

You will also develop knowledge of Pfizer’s complex manufacturing network, the CDMO competitive environment, the art of “getting things done” in a large organization, Pfizer’s broader goals and the interconnectedness of PC1 objectives.

ROLE RESPONSIBILITIES

Pfizer CentreOne Custom Business, China BD(Senior) Managerhas accountability for PC1 pipeline development and project management.

Generate sales leads and monitor competitive landscape within contract development and manufacture community in China

Primary point of contact for client site visit

Coordinate with site for feasibility evaluation for new PC1 opportunities resulting in go/no go decisions at Hangzhou site

Build relationships with key functional leaders responsible for delivering development and manufacturing services offered and engage their support of new business opportunities.

Achieve revenue budget based on the annual planning

Support line manager for business insights and strategy in support of marketing activities, content or materials that will drive brand awareness and help increase customer leads

Liaise and align with PGS (Sites, Quality Assurance, etc.), Research & Development, and Regulatory Affairs to accomplish business objectives

Own and manage the iNexus process for potential opportunities.

任职资格:

BASIC QUALIFICATIONS

This is a role which requires comprehensive knowledge and skills. The demands of the role require a candidate who possesses the following:

Experience:

8+ years of successful commercial, business development “Business to Business” or relevant experience

Knowledge of medicine development and manufacture process

Strong project management skills and rich experience

Good communication and engagement skills

Knowledge of the Chinese Biopharmaceutical market

Learning agility and an understanding of manufacturing processes

Ability to work and be successful in a matrixed environment with a high degree of flexibility

Fluency in Chinese and English

Education: 

BA/BS

PREFERRED QUALIFICATIONS

BA/BS in Bio-Chemistry, Engineering, Pharmacy, or a related technical discipline

MBA or advanced degree

Operational experience/exposure

iNexus process experience

辉瑞公司（Pfizer Inc.）创建于1849年，迄今已有160多年的历史，总部位于美国纽约，是目前全球***的以研发为基础的生物制药公司。辉瑞致力于运用创新的科学技术以及全球资源来改善每个生命阶段的健康和福祉。
我们的目标是“不断创新为患者带来能显著改善其健康的药物”。我们的使命是“成为一家卓越的创新型生物制药公司”。
2012年辉瑞公司全年合计收入590亿美元，研发投入78亿美元。辉瑞在全球拥有9万多名员工，59家生产基地，业务遍及全球150多个国家和地区。2012年财富全球500强企业中辉瑞排名126位。
目前辉瑞公司的产品覆盖了包括化学药物、生物制剂、疫苗、健康药物、动物保健品等用于人类、动物和消费者保健等诸多广泛而极具潜力的治疗及健康领域，同时其卓越的研发和生产能力处于全球领先地位。
在人类和动物药品的发现、开发和生产过程中，辉瑞始终致力于奉行严格的质量、安全和价值标准。每天，分布在世界各地的辉瑞员工致力于促进当地医疗卫生的发展以及探索能够应对当今最为棘手疾病的预防和治疗方案。
辉瑞还与世界各地的医疗卫生专业人士、政府和社区合作，支持世界各地的人们能够获得更为可靠和可承付的医疗卫生服务。这与辉瑞作为一家世界领先的生物制药公司的责任是一致的。160多年来，辉瑞一直努力为人们提供更好、更优质的服务。
辉瑞生物制药目前在华上市的创新药物已超过50个，其治疗领域涵盖了心脑血管及代谢、抗感染、中枢神经、抗炎镇痛、抗肿瘤、泌尿、疫苗及等诸多领域。其中如立普妥®、络活喜®、万艾可®、舒普深®、希舒美®、沛儿®、索坦®许多产品在市场上处于领先地位。为了让中国的广大患者能及时接受与全球同步的先进的药物治疗，辉瑞未来将进一步加大和加快在华新药引进和上市的力度和速度。
辉瑞健康药物旗下的善存®、钙尔奇®、惠菲宁®等消费保健产品也在中国市场家喻户晓，并以其优异的品质深受广大消费者的青睐；辉瑞旗下的硕腾动物保健品*为中国的动物保健市场提供各类领先的动物疫苗和动物药品。

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products of healthcare industry and many of the world's best-known healthcare products such as Centrum. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 160 years, Pfizer has worked to make a difference for all who rely on us.